News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
605,220 Results
Type
Article (43307)
Company Profile (324)
Press Release (561589)
Section
Business (169878)
Career Advice (2455)
Deals (30691)
Drug Delivery (107)
Drug Development (79022)
Employer Resources (149)
FDA (14656)
Job Trends (13144)
News (299522)
Policy (28948)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (4)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (5)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (14)
2024 Biotech Beach Digital (6)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (7)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (6)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
Academia (2695)
Academic (1)
Accelerated approval (3)
Adcomms (26)
Allergies (80)
Alliances (43684)
ALS (91)
Alzheimer's disease (1424)
Antibody-drug conjugate (ADC) (127)
Approvals (14644)
Artificial intelligence (236)
Autoimmune disease (20)
Automation (14)
Bankruptcy (326)
Best Places to Work (10799)
BIOSECURE Act (15)
Biosimilars (93)
Biotechnology (262)
Bladder cancer (65)
Brain cancer (27)
Breast cancer (254)
Cancer (2036)
Cardiovascular disease (179)
Career advice (2061)
Career pathing (31)
CAR-T (148)
Cell therapy (414)
Cervical cancer (19)
Clinical research (63866)
Collaboration (774)
Compensation (333)
Complete response letters (25)
COVID-19 (2567)
CRISPR (42)
C-suite (227)
Cystic fibrosis (101)
Data (1966)
Decentralized trials (2)
Denatured (15)
Depression (48)
Diabetes (249)
Diagnostics (5873)
Digital health (14)
Diversity (4)
Diversity, equity & inclusion (40)
Drug discovery (115)
Drug pricing (104)
Drug shortages (23)
Duchenne muscular dystrophy (90)
Earnings (62109)
Editorial (35)
Employer branding (20)
Employer resources (136)
Events (90437)
Executive appointments (665)
FDA (15740)
Featured Employer (44)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (686)
Gene editing (104)
Generative AI (21)
Gene therapy (305)
GLP-1 (724)
Government (4266)
Grass and pollen (4)
Guidances (45)
Healthcare (17496)
Huntington's disease (24)
IgA nephropathy (26)
Immunology and inflammation (119)
Indications (27)
Infectious disease (2703)
Inflammatory bowel disease (142)
Inflation Reduction Act (11)
Influenza (49)
Intellectual property (89)
Interviews (523)
IPO (14384)
IRA (45)
Job creations (2793)
Job search strategy (1693)
Kidney cancer (10)
Labor market (18)
Layoffs (451)
Leadership (19)
Legal (6190)
Liver cancer (71)
Lung cancer (301)
Lymphoma (129)
Machine learning (4)
Management (52)
Manufacturing (250)
MASH (68)
Medical device (11430)
Medtech (11434)
Mergers & acquisitions (16762)
Metabolic disorders (661)
Multiple sclerosis (73)
NASH (23)
Neurodegenerative disease (96)
Neuropsychiatric disorders (31)
Neuroscience (1944)
NextGen: Class of 2025 (6074)
Non-profit (4171)
Northern California (2243)
Now hiring (34)
Obesity (352)
Opinion (231)
Ovarian cancer (73)
Pain (81)
Pancreatic cancer (76)
Parkinson's disease (141)
Partnered (19)
Patents (202)
Patient recruitment (92)
Peanut (48)
People (54453)
Pharmaceutical (57)
Pharmacy benefit managers (13)
Phase I (20044)
Phase II (28206)
Phase III (21015)
Pipeline (1054)
Podcasts (68)
Policy (116)
Postmarket research (2404)
Preclinical (8448)
Press Release (67)
Prostate cancer (95)
Psychedelics (37)
Radiopharmaceuticals (257)
Rare diseases (383)
Real estate (4648)
Recruiting (61)
Regulatory (20465)
Reports (26)
Research institute (2295)
Resumes & cover letters (361)
Rett syndrome (3)
RNA editing (4)
RSV (37)
Schizophrenia (72)
Series A (120)
Series B (80)
Service/supplier (3)
Sickle cell disease (54)
Southern California (2021)
Special edition (13)
Spinal muscular atrophy (153)
Sponsored (27)
Startups (3209)
State (2)
Stomach cancer (14)
Supply chain (54)
The Weekly (52)
United States (19813)
Vaccines (642)
Venture capitalists (36)
Webinars (11)
Weight loss (245)
Women's health (28)
Worklife (16)
Date
Today (136)
Last 7 days (713)
Last 30 days (2704)
Last 365 days (32360)
2025 (7833)
2024 (33829)
2023 (37766)
2022 (48760)
2021 (52526)
2020 (50652)
2019 (43204)
2018 (32598)
2017 (30083)
2016 (28666)
2015 (33482)
2014 (25821)
2013 (21022)
2012 (22240)
2011 (23129)
2010 (20813)
Location
Africa (756)
Alabama (51)
Alaska (4)
Arizona (167)
Arkansas (12)
Asia (36773)
Australia (7263)
California (5204)
Canada (1805)
China (460)
Colorado (231)
Connecticut (230)
Delaware (128)
Europe (83171)
Florida (764)
Georgia (182)
Idaho (56)
Illinois (462)
India (22)
Indiana (261)
Iowa (6)
Japan (143)
Kansas (92)
Kentucky (21)
Louisiana (8)
Maine (50)
Maryland (798)
Massachusetts (3897)
Michigan (196)
Minnesota (327)
Mississippi (2)
Missouri (75)
Montana (25)
Nebraska (22)
Nevada (49)
New Hampshire (65)
New Jersey (1513)
New Mexico (26)
New York (1498)
North Carolina (887)
North Dakota (5)
Northern California (2243)
Ohio (172)
Oklahoma (10)
Oregon (32)
Pennsylvania (1147)
Puerto Rico (9)
Rhode Island (24)
South America (1028)
South Carolina (16)
South Dakota (1)
Southern California (2021)
Tennessee (84)
Texas (761)
Utah (162)
Virginia (122)
Washington D.C. (52)
Washington State (484)
West Virginia (3)
Wisconsin (43)
605,220 Results for "chiesi usa formerly known as cornerstone therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Chiesi USA Appoints Richard Smith as Vice President and Business Unit Leader, U.S. AIR
Chiesi USA, Inc. today announced it has appointed Richard Smith as vice president and business unit leader of U.S. AIR.
April 15, 2024
·
4 min read
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Bio NC
Chiesi to Present New Data Showcasing Depth of Respiratory Leadership at the American Thoracic Society 2024 International Conference
Chiesi USA, Inc. (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the presentation of eight abstracts from Chiesi’s global respiratory research portfolio at the American Thoracic Society (ATS) 2024 International Conference in San Diego from May 17-22, 2024.
May 16, 2024
·
6 min read
Business
Chiesi USA CEO Appointed to ASHP Foundation Board of Directors
Chiesi USA, Inc., a Cary-based specialty pharmaceutical company, announced that Jon Zwinski, CEO and General Manager at Chiesi USA, has been appointed to the American Society of Health-System Pharmacists Foundation Board of Directors.
July 20, 2023
·
4 min read
Press Releases
Lisata Therapeutics to Present at the Investival Showcase USA
March 6, 2025
·
1 min read
Press Releases
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
March 5, 2025
·
5 min read
Press Releases
Chiesi Global Rare Diseases Announces Multiple Presentations at 21st Annual WORLDSymposium™ Research Meeting
February 3, 2025
·
11 min read
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
January 21, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa
December 10, 2024
·
10 min read
Press Releases
Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC)
March 10, 2025
·
2 min read
1 of 60,522
Next
